[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367726-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367726-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","enhanced-detection-of-druggable-mutations-in-nonsmall-cell-lung-cancer-using-targeted-collection-of-bronchial-washing-fluid-compared-with-plasma-and-tumor-tissue","Enhanced Detection of Druggable Mutations in Non–Small Cell Lung Cancer Using Targeted Collection of Bronchial Washing Fluid Compared With Plasma and Tumor Tissue","","Prospective diagnostics study evaluates next-generation sequencing (NGS) performance for identifying druggable mutations in non–small cell lung cancer (NSCLC) using cell-free tumor DNA from bronchial washing fluid (BWF). Participants underwent NGS on three specimen types: BWF, plasma, and tumor tissue. The analysis compares detection rates and concordance, including co-occurring alteration assessment. Targeted BWF collection is assessed for feasibility, reliability, and safety, with adverse events monitored during collection.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/enhanced-detection-of-druggable-mutations-in-nonsmall-cell-lung-cancer-using-targeted-collection-of-bronchial-washing-fluid-compared-with-plasma-and-tumor-tissue/367726/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/enhanced-detection-of-druggable-mutations-in-nonsmall-cell-lung-cancer-using-targeted-collection-of-bronchial-washing-fluid-compared-with-plasma-and-tumor-tissue/367726.png","ImageObject",300,407,{"name":42,"@type":43},"supergirl","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What specimens were compared for NGS in this study?","Question",{"text":63,"@type":64},"NGS was performed on three simultaneous specimen types: bronchial washing fluid (BWF), plasma, and tumor tissue collected during bronchoscopy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the detection rate of druggable mutations in BWF compare with plasma and tissue?",{"text":68,"@type":64},"In the full patient set, druggable mutations were detected in BWF at a higher rate (65%) than plasma (47%) and tumor tissue (48%).",{"name":70,"@type":61,"acceptedAnswer":71},"How strong was the agreement between BWF and tumor tissue for detecting druggable mutations?",{"text":72,"@type":64},"The concordance rate between BWF and tissue for detecting druggable mutations was 94% in the analysis intent group.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367726,1790387294,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Original Reports | Diagnostics  \nEnhanced Detection of Druggable Mutations in Non–Small Cell Lung Cancer Using Targeted Collection of Bronchial Washing Fluid Compared With Plasma and Tumor Tissue  \nMi-Hyun Kim, MD, PhD1,2,3 ; Soo Han Kim, MD, PhD1,2; Hayoung Seong, MD1,2; and Jung Seop Eom, MD, PhD1,2,3   \nDOI [https://doi.org/10.1200/PO-25-00299](https://doi.org/10.1200/PO-25-00299)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Next-generation sequencing (NGS) has become the gold standard for the molecular testing of patients with non–small cell lung cancer (NSCLC) . This prospective study evaluated the performance of NGS using cell-free tumor DNA (ctDNA) extracted from bronchial washing ﬂuid (BWF) collected via a targeted washing technique to detect druggable mutations. |\n| MATERIALS\u003Cbr>AND METHODS | All study participants simultaneously underwent NGS using three sample types:\u003Cbr>(1) BWF,(2) plasma, and (3) tumor tissue collected during bronchoscopy. The full patient set (FPS) included all enrolled patients, whereas the analysis intent group (AIG) included patients who underwent successful NGS across all specimen types (BWF, plasma, and tissue) . |\n| RESULTS | Sixty and 50 patients were included in the FPS and AIG groups, respectively. In FPS, the detection rate of druggable mutations in BWF using NGS was 65%, which was signiﬁcantly higher than that of plasma (47%) and tissue samples (48%; P 5 .003 and P 5 .002, respectively) . In the AIG, the concordance rate for detecting druggable mutations between BWF and tissue samples was 94% . In addition, the detection rate of co-occurring genetic alterations in BWF using NGS was signiﬁcantly higher than that in plasma samples (92% v 64%, P 5 .001), whereas it was comparable with that in tissue samples (92% v 94%, P 5 1.000) . No signiﬁcant adverse events occurred during the BWF collection. |\n| CONCLUSION | NGS using ctDNA from BWF obtained through a targeted washing technique is a feasible and reliable method for genomic proﬁling of NSCLC, providing a promising approach for identifying druggable mutations. |\n\nACCOMPANYING CONTENT  \n Data Supplement  \nAccepted July 10, 2025  \nPublished August 1, 2025  \nJCO Precis Oncol 9:e2500299 © 2025 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nThe discovery of oncogenic drivers and the development of targeted therapies have revolutionized the treatment landscape for non–small cell lung cancer (NSCLC) .1 These advancements have underscored the signiﬁcance of molecular testing for the identiﬁcation of speciﬁc genomic alterations (GAs) .2 In particular, the advent of targeted agents for rare oncogenic drivers, such as human epidermal growth factor receptor 2 (HER2) mutations or mesenchymal– epithelial transition (MET) exon 14 skipping mutations, has underscored the necessity of comprehensive genomic proﬁling.3 ,4 Traditionally, mutational testing for NSCLC relies on single-gene reﬂex tests, such as peptide nucleic acid–mediated real-time polymerase chain reaction clamping for detecting epidermal growth factor receptor (EGFR) mutations. However, recent shifts have favored next-generation sequencing (NGS), which allows for more detailed and extensive analysis of multiple GAs.5  \nAlthough NGS is considered essential, challenges persist regarding the specimens used for NGS testing in NSCLC.6 Tissue specimens have traditionally been regarded as the standard samples for NGS testing; however, several concerns have been associated with tissue-based NGS testing: (1) the requirement for large amounts oftissue, which increases the invasiveness of the biopsy procedure; (2) prolonged turnaround times; (3) the infeasibility of rebiopsy on disease progression; and (4) the inability to overcome tumor heterogeneity.7 On the other hand, NGS testing using plasma samples is considered minimally invasive with a rapid turnaround time; however, relatively lower sensitivity can result in f","cbCaitGIC2RqQJd0","https://ap.wps.com/l/cbCaitGIC2RqQJd0","pdf",850775,11,"English","# Purpose\n# Materials and Methods\n# Results\n# Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"What specimens were compared for NGS in this study?\",\"answer\":\"NGS was performed on three simultaneous specimen types: bronchial washing fluid (BWF), plasma, and tumor tissue collected during bronchoscopy.\"},{\"question\":\"How did the detection rate of druggable mutations in BWF compare with plasma and tissue?\",\"answer\":\"In the full patient set, druggable mutations were detected in BWF at a higher rate (65%) than plasma (47%) and tumor tissue (48%).\"},{\"question\":\"How strong was the agreement between BWF and tumor tissue for detecting druggable mutations?\",\"answer\":\"The concordance rate between BWF and tissue for detecting druggable mutations was 94% in the analysis intent group.\"}]","Enhanced Detection of Druggable Mutations in Non–Small Cell Lung Cancer Using Targeted Collection of Bronchial Washing Fluid Compared With Plasma and Tumor Tissue | PDF",1790172282,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/528333c129072a972c55030a636383d7.webp",983,1315,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5529d6a630c3119c4c42e56f11b55c50.webp",982,1314,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/667bafbf433d178f0ed91533cbace123.webp",981,1312,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2e1a7442fbde40b42ace935ff7e7bb3.webp",980,1311]